

Simon P L Travis

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3683901/simon-p-l-travis-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

181
papers

15,749
citations

53
h-index

124
g-index

205
ext. papers

18,667
ext. citations

6.7
avg, IF

6.33
L-index

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 181 | Divergent trajectories of antiviral memory after SARS-CoV-2 infection.. <i>Nature Communications</i> , 2022 , 13, 1251 | 17.4 | 1 |
| 180 | Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 390-399 | 6.1 | 1 |
| 179 | Defactinib inhibits PYK2 phosphorylation of IRF5 and reduces intestinal inflammation. <i>Nature Communications</i> , 2021 , 12, 6702 | 17.4 | 1 |
| 178 | High mucosal cytomegalovirus DNA helps predict adverse short-term outcome in acute severe ulcerative colitis. <i>Intestinal Research</i> , 2021 , 19, 438-447 | 4.1 | 3 |
| 177 | IL-1-driven stromal-neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies. <i>Nature Medicine</i> , 2021 , 27, 1970-1981 | 50.5 | 11 |
| 176 | Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. <i>Cell</i> , 2021 , 184, 5699-5714.e11 | 56.2 | 64 |
| 175 | Gut microbiota: sculptors of the intestinal stem cell niche in health and inflammatory bowel disease. <i>Gut Microbes</i> , 2021 , 13, 1990827 | 8.8 | 7 |
| 174 | Clinical Genomics for the Diagnosis of Monogenic Forms of Inflammatory Bowel Disease: A Position Paper From the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2021 , 72, 456-473 | 2.8 | 19 |
| 173 | Using item response theory (IRT) to improve the efficiency of the Simple Clinical Colitis Activity Index (SCCAI) for patients with ulcerative colitis. <i>BMC Gastroenterology</i> , 2021 , 21, 132 | 3 | 1 |
| 172 | The gut microbiota as a therapeutic target for obesity: a scoping review. <i>Nutrition Research Reviews</i> , 2021 , 1-14 | 7 | 4 |
| 171 | The pediatric ulcerative colitis activity index (PUCAI) predicts steroid-failure in adults with acute severe colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2021 , 56, 1049-1055 | 2.4 | |
| 170 | Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 836-847 | 4.5 | 9 |
| 169 | Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance. <i>Gut</i> , 2021 , 70, 1023-1036 | 19.2 | 15 |
| 168 | Gut microbiome diversity in acute severe colitis is distinct from mild to moderate ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 731-739 | 4 | 8 |
| 167 | Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 568-576 | 6.1 | 2 |
| 166 | Stress-related consequences of the coronavirus disease 2019 pandemic on symptoms of Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 , 33, 1511-1516 | 2.2 | 2 |
| 165 | Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic. <i>Gut</i> , 2021 , 70, 2398-2400 | 19.2 | 5 |

| | | | |
|-----|---|------|----|
| 164 | Overexpression of Cancer-Associated Stem Cell Gene OLFM4 in the Colonic Epithelium of Patients With Primary Sclerosing Cholangitis. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 1316-1327 | 4.5 | 5 |
| 163 | Inflammatory Bowel Disease in Patients with Congenital Chloride Diarrhoea. <i>Journal of Crohn's and Colitis</i> , 2021 , 15, 1679-1685 | 1.5 | 2 |
| 162 | Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis. <i>Current Medical Research and Opinion</i> , 2021 , 37, 1891-1900 | 2.5 | 3 |
| 161 | Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis.. <i>Scandinavian Journal of Gastroenterology</i> , 2021 , 1-8 | 2.4 | 2 |
| 160 | Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. <i>Gut</i> , 2020 , 69, 658-664 | 19.2 | 8 |
| 159 | Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 1446-1461 | 1.5 | 8 |
| 158 | Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. <i>Gastroenterology</i> , 2020 , 159, 139-147 | 13.3 | 54 |
| 157 | Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 1562-1571 | 4.5 | 12 |
| 156 | Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease. <i>Nature Communications</i> , 2020 , 11, 995 | 17.4 | 21 |
| 155 | Short- and long-term outcomes of strictureplasty for obstructive Crohn's disease. <i>Colorectal Disease</i> , 2020 , 22, 1159-1168 | 2.1 | 4 |
| 154 | Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia. <i>Rheumatology</i> , 2020 , 59, 2166-2168 | 3.9 | 9 |
| 153 | Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. <i>World Journal of Gastroenterology</i> , 2020 , 26, 4428-4441 | 5.6 | 6 |
| 152 | Does Smoking Cessation Reduce Surgical Recurrence After Primary Ileocolic Resection for Crohn's Disease?. <i>Diseases of the Colon and Rectum</i> , 2020 , 63, 200-206 | 3.1 | 3 |
| 151 | Is Crohn's Disease a Rightly Used Eponym?. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 867-871 | 1.5 | 1 |
| 150 | Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 149-157 | 6.1 | 11 |
| 149 | Loss of IL-10 signaling in macrophages limits bacterial killing driven by prostaglandin E2. <i>Journal of Experimental Medicine</i> , 2020 , 217, | 16.6 | 23 |
| 148 | Prevalence and long-term outcome of sub-clinical primary sclerosing cholangitis in patients with ulcerative colitis. <i>Liver International</i> , 2020 , 40, 2744-2757 | 7.9 | 5 |
| 147 | Remission of Inflammatory Bowel Disease in Glucose-6-Phosphatase 3 Deficiency by Allogeneic Haematopoietic Stem Cell Transplantation. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 142-147 | 1.5 | 12 |

| | | | |
|-----|--|------|----|
| 146 | The impact of intestinal transplantation on quality of life. <i>Clinical Nutrition</i> , 2020 , 39, 1958-1967 | 5.9 | 6 |
| 145 | IM-UNITI at Three Years: Stellar Stelara or Stardust? The Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 1-3 | 1.5 | 4 |
| 144 | The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 192-204 | 1.5 | 23 |
| 143 | Head-to-head trials in inflammatory bowel disease: past, present and future. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 365-376 | 24.2 | 20 |
| 142 | Interfering with leukocyte trafficking in Crohn's disease. <i>Baillieres's Best Practice and Research in Clinical Gastroenterology</i> , 2019 , 38-39, 101617 | 2.5 | 13 |
| 141 | Autologous stem cell transplantation in refractory Crohn's disease - low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study. <i>BMC Gastroenterology</i> , 2019 , 19, 82 | 3 | 12 |
| 140 | Magnetic resonance enterography compared with ultrasonography in newly diagnosed and relapsing Crohn's disease patients: the METRIC diagnostic accuracy study. <i>Health Technology Assessment</i> , 2019 , 23, 1-162 | 4.4 | 3 |
| 139 | Improving the quality of care for inflammatory bowel disease. <i>Intestinal Research</i> , 2019 , 17, 45-53 | 4.1 | 10 |
| 138 | Real-time data monitoring for ulcerative colitis: patient perception and qualitative analysis. <i>Intestinal Research</i> , 2019 , 17, 365-374 | 4.1 | 6 |
| 137 | Visceral Adipose Tissue Is Associated With Stricturing Crohn's Disease Behavior, Fecal Calprotectin, and Quality of Life. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 592-600 | 4.5 | 19 |
| 136 | Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis-a Prospective Analysis. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, 424-430 | 1.5 | 37 |
| 135 | Authors'Reply: The Association Between Visceral Adipose Tissue and Stricturing Crohn's Disease Behavior, Fecal Calprotectin and Quality of Life. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, e62-e63 | 4.5 | |
| 134 | Diagnostic Yield of Dysplasia in Polyp-adjacent Biopsies for Patients with Inflammatory Bowel Disease: A Cross-sectional Study. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 670-676 | 1.5 | 15 |
| 133 | NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease. <i>Mucosal Immunology</i> , 2018 , 11, 562-574 | 9.2 | 51 |
| 132 | Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-an International, Cross-disciplinary Consensus. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 408-418 | 1.5 | 66 |
| 131 | Chromoendoscopy versus autofluorescence imaging for neoplasia detection in patients with longstanding ulcerative colitis (FIND-UC): an international, multicentre, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 305-316 | 18.8 | 21 |
| 130 | Development of an index to define overall disease severity in IBD. <i>Gut</i> , 2018 , 67, 244-254 | 19.2 | 73 |
| 129 | Endoscopy in Inflammatory Bowel Disease: Western Perspective Europe 2018 , 275-282 | | |

| | | | |
|-----|---|------|-----|
| 128 | Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn's disease (METRIC): a multicentre trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 548-558 | 18.8 | 70 |
| 127 | Why is it so difficult to evaluate faecal microbiota transplantation as a treatment for ulcerative colitis?. <i>Intestinal Research</i> , 2018 , 16, 209-215 | 4.1 | 8 |
| 126 | Analysis of the Gut Microbiome of Rural and Urban Healthy Indians Living in Sea Level and High Altitude Areas. <i>Scientific Reports</i> , 2018 , 8, 10104 | 4.9 | 57 |
| 125 | Plasma Nuclear Magnetic Resonance Metabolomics Discriminates Between High and Low Endoscopic Activity and Predicts Progression in a Prospective Cohort of Patients With Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 1326-1337 | 1.5 | 18 |
| 124 | Correlation Between Endoscopic and Histological Activity in Ulcerative Colitis Using Validated Indices. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 1151-1157 | 1.5 | 18 |
| 123 | Potential of Fecal Calprotectin as an Objective Marker to Discriminate Hospitalized Patients with Acute Severe Colitis from Outpatients with Less Severe Disease. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 2747-2753 | 4 | 1 |
| 122 | IBD2020 global forum: results of an international patient survey on quality of care. <i>Intestinal Research</i> , 2018 , 16, 537-545 | 4.1 | 5 |
| 121 | Are Truelove and Witts criteria for diagnosing acute severe colitis relevant for the Indian population? A prospective study. <i>Intestinal Research</i> , 2018 , 16, 69-74 | 4.1 | 7 |
| 120 | Limited uptake of ulcerative colitis "treat-to-target" recommendations in real-world practice. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 599-607 | 4 | 21 |
| 119 | Predictors of long-term outcomes in patients with acute severe colitis: A northern Indian cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 615-622 | 4 | 15 |
| 118 | What's app? Electronic health technology in inflammatory bowel disease. <i>Intestinal Research</i> , 2018 , 16, 366-373 | 4.1 | 17 |
| 117 | Diagnostic Accuracy of Endoscopic Trimodal Imaging and Chromoendoscopy for Lesion Characterization in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 1438-1447 | 1.5 | 8 |
| 116 | Obesity in Inflammatory Bowel Disease: Gains in Adiposity despite High Prevalence of Myopenia and Osteopenia. <i>Nutrients</i> , 2018 , 10, | 6.7 | 30 |
| 115 | Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 905-919 | 1.5 | 13 |
| 114 | Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes From the European Society for Blood and Marrow Transplantation. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 1097-1103 | 1.5 | 22 |
| 113 | Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. <i>Gastrointestinal Endoscopy</i> , 2018 , 88, 360-369.e2 | 5.2 | 15 |
| 112 | Development and validation of the Nancy histological index for UC. <i>Gut</i> , 2017 , 66, 43-49 | 19.2 | 196 |
| 111 | Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 801-813 | 6.1 | 64 |

| | | | |
|-----|---|------|-----|
| 110 | Th1 and Innate Lymphoid Cells Accumulate in Primary Sclerosing Cholangitis-associated Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 1124-1134 | 1.5 | 26 |
| 109 | Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 3-15 | 6.1 | 82 |
| 108 | Faecal Calprotectin and UCEIS Predict Short-term Outcomes in Acute Severe Colitis: Prospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 1309-1316 | 1.5 | 24 |
| 107 | Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. <i>Nature Medicine</i> , 2017 , 23, 579-589 | 50.5 | 344 |
| 106 | Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. <i>Lancet, The</i> , 2017 , 390, 2779-2789 | 40 | 403 |
| 105 | Beyond Histological Remission: Intramucosal Calprotectin as a Potential Predictor of Outcomes in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 460-467 | 1.5 | 8 |
| 104 | Patient Reported Outcome Measures (PROMs) in Inflammatory Bowel Disease: New Data. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, S576-S585 | 1.5 | 30 |
| 103 | Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 1317-1325 | 1.5 | 26 |
| 102 | Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 399-406 | 18.8 | 52 |
| 101 | Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 246-255 | 1.5 | 13 |
| 100 | Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells. <i>Journal of Allergy and Clinical Immunology</i> , 2017 , 139, 607-620.e15 | 11.5 | 45 |
| 99 | The role of a defunctioning stoma for colonic and perianal Crohn's disease in the biological era. <i>Scandinavian Journal of Gastroenterology</i> , 2017 , 52, 251-256 | 2.4 | 14 |
| 98 | Predicting the Individual Risk of Acute Severe Colitis at Diagnosis. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 335-341 | 1.5 | 14 |
| 97 | Current best practice for disease activity assessment in IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016 , 13, 567-79 | 24.2 | 117 |
| 96 | Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016 , 1, 15-24 | 18.8 | 124 |
| 95 | Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. <i>Gut</i> , 2016 , 65, 408-14 | 19.2 | 225 |
| 94 | Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016 , 10, 607-18 | 1.5 | 23 |
| 93 | Central Endoscopy Reading in Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2016 , 10 Suppl 2, S542-7 | 1.5 | 12 |

| | | | |
|----|--|------|-----|
| 92 | Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016 , 1, 273-282 | 18.8 | 63 |
| 91 | The Crohn's Disease-Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, e121-2 | 6.9 | 2 |
| 90 | Toxic dilatation of the colon. <i>Medicine</i> , 2015 , 43, 171-173 | 0.6 | 1 |
| 89 | Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. <i>The Cochrane Library</i> , 2015 , | 5.2 | 2 |
| 88 | The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 607-16 | 1.5 | 40 |
| 87 | Introducing vedolizumab to clinical practice: who, when, and how?. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 356-66 | 1.5 | 44 |
| 86 | Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. <i>Lancet, The</i> , 2015 , 386, 137-44 | 4.0 | 143 |
| 85 | Does Disease Extent Matter when Scoring the UCEIS?. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 694 | 1.5 | 3 |
| 84 | Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. <i>BMJ Open</i> , 2015 , 5, e007230 | 3 | 40 |
| 83 | Reduced sodium/proton exchanger NHE3 activity causes congenital sodium diarrhea. <i>Human Molecular Genetics</i> , 2015 , 24, 6614-23 | 5.6 | 80 |
| 82 | Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 738-46 | 1.5 | 23 |
| 81 | Conventional drug therapy for inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2015 , 50, 90-112 | 2.4 | 44 |
| 80 | Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 2475-82 | 4.5 | 23 |
| 79 | Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 601-6 | 1.5 | 47 |
| 78 | Association between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 376-81 | 1.5 | 75 |
| 77 | Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 2524-34 | 27.4 | 102 |
| 76 | Response to Villanacci et. al. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 429 | 1.5 | |
| 75 | Endoscopic Disease Activity in Inflammatory Bowel Disease. <i>Current Gastroenterology Reports</i> , 2015 , 17, 50 | 5 | 10 |

| | | | |
|----|--|------|-----|
| 74 | ReMonade Legs® Why do Some Patients Get Profound Hypomagnesaemia on Proton-Pump Inhibitors?. <i>Intestinal Research</i> , 2015 , 13, 227-32 | 4.1 | 9 |
| 73 | Acute variceal haemorrhage in the United Kingdom: patient characteristics, management and outcomes in a nationwide audit. <i>Digestive and Liver Disease</i> , 2014 , 46, 419-26 | 3.3 | 59 |
| 72 | Thrombosis in inflammatory bowel disease: are we tailoring prophylaxis to those most at risk?. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 166-71 | 1.5 | 18 |
| 71 | Poor outcomes in hospitalized patients with gastrointestinal bleeding: impact of baseline risk, bleeding severity, and process of care. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1603-12 | 0.7 | 16 |
| 70 | METRIC (MREnterography or uLTRasound in Crohn's disease): a study protocol for a multicentre, non-randomised, single-arm, prospective comparison study of magnetic resonance enterography and small bowel ultrasound compared to a reference standard in those aged 16 and over. <i>BMC Gastroenterology</i> , 2014 , 14, 142 | 3 | 28 |
| 69 | Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2014 , 24, 367-78 | 3.3 | 74 |
| 68 | Unexplained gastrointestinal symptoms: think mitochondrial disease. <i>Digestive and Liver Disease</i> , 2014 , 46, 1-8 | 3.3 | 24 |
| 67 | Outcomes after ileal pouch anal anastomosis in patients with primary sclerosing cholangitis. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 662-70 | 1.5 | 35 |
| 66 | Comparing disease activity indices in ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 318-25 | 1.5 | 67 |
| 65 | Systematic review: histological remission in inflammatory bowel disease. Is Complete Remission the new treatment paradigm? An IOIBD initiative. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 1582-97 | 1.5 | 176 |
| 64 | Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. <i>Gut</i> , 2014 , 63, 433-41 | 19.2 | 173 |
| 63 | Placebo response rate in clinical trials of fistulizing Crohn's disease: systematic review and meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 1981-90 | 6.9 | 21 |
| 62 | The diagnostic approach to monogenic very early onset inflammatory bowel disease. <i>Gastroenterology</i> , 2014 , 147, 990-1007.e3 | 13.3 | 422 |
| 61 | Assessment of Disease Activity in Ulcerative Colitis 2014 , 345-357 | | |
| 60 | Tu1106 Observer Agreement and Construct Validity in Central Endoscopic Assessment of Disease Activity in Ulcerative Colitis. <i>Gastroenterology</i> , 2013 , 144, S-763 | 13.3 | 3 |
| 59 | Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2013 , 7, e449-56 | 1.5 | 36 |
| 58 | The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. <i>Gastroenterology</i> , 2013 , 145, 149-157.e2 | 13.3 | 157 |
| 57 | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. <i>Journal of Crohn's and Colitis</i> , 2013 , 7, 1-33 | 1.5 | 361 |

| | | | |
|----|---|------|-----|
| 56 | Prevalence, management, and outcomes of patients with coagulopathy after acute nonvariceal upper gastrointestinal bleeding in the United Kingdom. <i>Transfusion</i> , 2013 , 53, 1069-76 | 2.9 | 35 |
| 55 | 554 Correlation Between the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and Outcomes in Acute Severe Ulcerative Colitis. <i>Gastroenterology</i> , 2013 , 144, S-102 | 13.3 | 4 |
| 54 | Reliability and initial validation of the ulcerative colitis endoscopic index of severity. <i>Gastroenterology</i> , 2013 , 145, 987-95 | 13.3 | 254 |
| 53 | Mucosal healing in inflammatory bowel diseases: a systematic review. <i>Gut</i> , 2012 , 61, 1619-35 | 19.2 | 511 |
| 52 | Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. <i>Gut</i> , 2012 , 61, 1693-700 | 19.2 | 995 |
| 51 | The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy. <i>Journal of Crohn's and Colitis</i> , 2012 , 6 Suppl 2, S250-9 | 1.5 | 20 |
| 50 | Once-daily budesonide MMX [®] extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. <i>Gastroenterology</i> , 2012 , 143, 1218-1226.e2 | 13.3 | 167 |
| 49 | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. <i>Journal of Crohn's and Colitis</i> , 2012 , 6, 991-1030 | 1.5 | 715 |
| 48 | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. <i>Journal of Crohn's and Colitis</i> , 2012 , 6, 965-90 | 1.5 | 592 |
| 47 | Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). <i>Gut</i> , 2012 , 61, 535-42 | 19.2 | 328 |
| 46 | Behandlungsergebnisse der akuten oberen nicht varikölen gastrointestinalen Blutung in Relation zum Zeitpunkt der Endoskopie: Resultate einer landesweiten Studie. <i>Endoskopie Heute</i> , 2012 , 25, 196-204 | | |
| 45 | Assessing disease activity in patients with ulcerative colitis. <i>Gastroenterology and Hepatology</i> , 2012 , 8, 751-4 | 0.7 | 7 |
| 44 | Conventional medical management of inflammatory bowel disease. <i>Gastroenterology</i> , 2011 , 140, 1827-1837.e2164 | 13.3 | 164 |
| 43 | IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. <i>Journal of Experimental Medicine</i> , 2011 , 208, 1127-33 | 16.6 | 489 |
| 42 | Does it all ADA up? Adalimumab for ulcerative colitis. <i>Gut</i> , 2011 , 60, 741-2 | 19.2 | 6 |
| 41 | The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. <i>American Journal of Gastroenterology</i> , 2011 , 106, 1593-602; quiz 1593, 1603 | 0.7 | 291 |
| 40 | The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. <i>American Journal of Gastroenterology</i> , 2011 , 106, 1594-602; quiz 1593, 1603 | 0.7 | 60 |
| 39 | Colon salvage therapy for acute severe colitis: cyclosporine or infliximab?. <i>Current Opinion in Gastroenterology</i> , 2011 , 27, 358-62 | 3 | 10 |

| | | | |
|----|--|------|------|
| 38 | Induction of remission with oral budesonide MMX [®] (9 mg) tablets in patients with mild to moderate, active Ulcerative Colitis: A multicenter, open-label efficacy and safety study. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, S20 | 4.5 | 3 |
| 37 | Review article: defining remission in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 113-24 | 6.1 | 145 |
| 36 | Exposure to hookworms in patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 1248-9 | 6.1 | 2 |
| 35 | Red blood cell transfusion practice in patients presenting with acute upper gastrointestinal bleeding: a survey of 815 UK clinicians. <i>Transfusion</i> , 2011 , 51, 1940-8 | 2.9 | 20 |
| 34 | Development of the Crohn's disease digestive damage score, the Lhann score. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 1415-22 | 4.5 | 395 |
| 33 | Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers. <i>Gut</i> , 2011 , 60, 3-9 | 19.2 | 61 |
| 32 | The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. <i>Journal of Crohn's and Colitis</i> , 2010 , 4, 63-101 | 1.5 | 578 |
| 31 | The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. <i>Journal of Crohn's and Colitis</i> , 2010 , 4, 28-62 | 1.5 | 1071 |
| 30 | The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. <i>Journal of Crohn's and Colitis</i> , 2010 , 4, 7-27 | 1.5 | 808 |
| 29 | The pattern and outcome of acute severe colitis. <i>Journal of Crohn's and Colitis</i> , 2010 , 4, 431-7 | 1.5 | 206 |
| 28 | Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. <i>British Journal of Surgery</i> , 2010 , 97, 404-9 | 5.3 | 160 |
| 27 | Long-term outcome after admission for acute severe ulcerative colitis in Oxford: the 1992-1993 cohort. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 823-8 | 4.5 | 48 |
| 26 | Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 1599-604 | 4.5 | 84 |
| 25 | An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial. <i>Journal of Crohn's and Colitis</i> , 2009 , 3, 32-7 | 1.5 | 9 |
| 24 | An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial. <i>Journal of Crohn's and Colitis</i> , 2009 , 3, 168-74 | 1.5 | 8 |
| 23 | The role of CMV in steroid-resistant ulcerative colitis: A systematic review. <i>Journal of Crohn's and Colitis</i> , 2009 , 3, 141-8 | 1.5 | 52 |
| 22 | The management of acute severe colitis: ACPGBI position statement. <i>Colorectal Disease</i> , 2008 , 10 Suppl 3, 8-29 | 2.1 | 39 |
| 21 | Obstructing giant post-inflammatory polyposis in ulcerative colitis: Case report and review of the literature. <i>Journal of Crohn's and Colitis</i> , 2008 , 2, 170-80 | 1.5 | 25 |

| | | | |
|----|---|------|-----|
| 20 | European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. <i>Journal of Crohn's and Colitis</i> , 2008 , 2, 1-23 | 1.5 | 402 |
| 19 | Recurrent posterior scleritis and orbital myositis as extra-intestinal manifestations of Crohn's disease: Case report and systematic literature review. <i>Journal of Crohn's and Colitis</i> , 2008 , 2, 337-42 | 1.5 | 26 |
| 18 | The role of blood transfusion in the management of upper and lower intestinal tract bleeding. <i>Baillieres's Best Practice and Research in Clinical Gastroenterology</i> , 2008 , 22, 355-71 | 2.5 | 10 |
| 17 | Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. <i>Trials</i> , 2007 , 8, 17 | 2.8 | 95 |
| 16 | Red cell transfusion for the management of upper gastrointestinal haemorrhage 2007 , | | 2 |
| 15 | European evidence based consensus on the diagnosis and management of Crohn's disease: current management. <i>Gut</i> , 2006 , 55 Suppl 1, i16-35 | 19.2 | 443 |
| 14 | New thinking: theory vs practice. A case study illustrating evidence-based therapeutic decision making. <i>Colorectal Disease</i> , 2006 , 8 Suppl 1, 25-9 | 2.1 | 3 |
| 13 | Review article: induction therapy for patients with active ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 24 Suppl 1, 10-6 | 6.1 | 33 |
| 12 | Conduct of Clinical Trials in UC. <i>American Journal of Gastroenterology</i> , 2006 , 101, S429-S430 | 0.7 | 3 |
| 11 | Dose escalation of 5ASA: does it work?. <i>Digestive and Liver Disease</i> , 2005 , 37, 82-4 | 3.3 | 1 |
| 10 | RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2005 , 11, 713-9 | 4.5 | 84 |
| 9 | Advances in therapeutic approaches to ulcerative colitis and Crohn's disease. <i>Current Gastroenterology Reports</i> , 2005 , 7, 475-84 | 5 | 19 |
| 8 | What is the optimal dosage of mesalazine to maintain remission in patients with ulcerative colitis?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2005 , 2, 564-5 | | 3 |
| 7 | Review article: the management of mild to severe acute ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 20 Suppl 4, 88-92 | 6.1 | 23 |
| 6 | Guidelines for the management of inflammatory bowel disease in adults. <i>Gut</i> , 2004 , 53 Suppl 5, V1-16 | 19.2 | 774 |
| 5 | 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. <i>Gastroenterology</i> , 2004 , 126, 1733-9 | 13.3 | 125 |
| 4 | Predicting outcome in severe ulcerative colitis. <i>Digestive and Liver Disease</i> , 2004 , 36, 448-9 | 3.3 | 10 |
| 3 | Recent advances in immunomodulation in the treatment of inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2003 , 15, 215-8 | 2.2 | 10 |

2 Which 5-ASA?. *Gut*, **2002**, 51, 548-9

19.2 7

1 IL-1-driven stromal-neutrophil interaction in deep ulcers defines a pathotype of therapy non-responsive inflammatory bowel disease

1